Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and […]
Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207
Bridge Biotherapeutics, a clinical-stage biotech company based in South Korea and Cambridge that is advancing novel drugs for […]
Samyang Holdings Enters Partnership with LG Chem for the Development of Innovative Cancer Therapeutics
Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement on […]
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Tubulis and Bristol Myers Squibb today announced that they have entered into a strategic license […]
Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate
Nutcracker Therapeutics, a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology […]
Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization of Lead Bifunctional Antibody Program, BCA101
Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable […]
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
IDEAYA Biosciences, a precision medicine oncology company committed to the discovery and development of targeted […]
TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023
Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, announced […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more